Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2016—GlycoMark has partnered with Diazyme Laboratories to offer a diabetes panel to test three different measures of glycemic control on one specimen. The panel includes assays that measure both intermediate- and long-term glucose averages (Diazyme’s Glycated Serum Protein/GSP and Enzymatic HbA1c) along with the GlycoMark test.
October 2016—DRG International showcased its Aldosterone ELISA kit for the measurement of aldosterone in serum, plasma, and urine. Aldosterone regulates levels of sodium and potassium in the body and controls blood pressure as well as fluids and electrolytes in the blood. Measurement of aldosterone levels in serum in conjunction with plasma renin levels (aldosterone/renin ratio) can be used to differentiate between primary and secondary aldosteronism, which is vital in the treatment and management of the disease. The kit is available worldwide and is for research use only in the United States.
October 2016—Beckman Coulter, an operating company of Danaher, and Augusta University (Ga.) Medical Center signed a 15-year master service agreement. The alliance aims to create innovative models of care using technology and process improvement methodologies in the laboratory setting, ultimately providing enhanced patient care and significant long-term cost savings for the medical center.
October 2016—U.K.-based Angle plc presented a poster by researchers from the University of Texas MD Anderson Cancer Center describing clinically relevant results from a study using Angle’s Parsortix cell separation system to harvest breast cancer cells in blood for subsequent molecular characterization. The research team, led by James M. Reuben, PhD, professor, Department of Hematopathology, MD Anderson Cancer Center, confirmed the ability to perform advanced molecular analysis on breast cancer cells isolated from blood samples using the Parsortix liquid biopsy technology. The researchers note the ability of the Parsortix method to harvest circulating tumor cells without the use of antibodies.
October 2016—Bio-Rad Laboratories launched Amplichek II quality control, which was issued a de novo clearance from the FDA. Amplichek II is the first in a series of infectious disease controls that the company is introducing to the molecular diagnostic testing market. It is an independent, multianalyte quality control that monitors the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of health care–associated infections.
October 2016—Abingdon Health announced the CE marking and FDA registration of its immunoassay reader, the ADxLR5, as a class I medical device. The ADxLR5 lateral flow device reader is designed to offer the most up-to-date features required for rapid testing, including a touchscreen user interface, barcode sample identification, stored calibration curve processing, and Wi-Fi or wired connectivity.
October 2016—Abbott introduced Alinity, its harmonized family of next-generation systems across immunoassay, clinical chemistry, point-of-care, hematology, blood and plasma screening, and molecular diagnostics. Each Alinity platform will include a number of features to help institutions, clinicians, and laboratorians better navigate through the health care environment.
October 2016—Instrumentation Laboratory introduced several innovations in hemostasis at the meeting, including the FDA 510(k)-cleared HemosIL HIT-Ab(PF4-H) assay for use on ACL Top Family Hemostasis Testing Systems. The fully automated, on-demand assay for heparin-induced thrombocytopenia detects antibodies associated with HIT on a hemostasis testing system.
October 2016—Advanced Instruments launched its GloCyte Automated Cell Counter System. The company announced in July that it received 510(k) clearance from the Food and Drug Administration to market its GloCyte Automated Cell Counter System and GloCyte Low and High Level Controls.
September 2016—Horizon Discovery Group and the Wistar Institute announced that Horizon has taken an exclusive license to 153 of Wistar’s melanoma patient-derived xenograft models. Horizon’s distribution of the Wistar melanoma PDX collection will allow scientists worldwide to investigate the efficacy and safety of its drugs prior to trials in human populations.
